Lobbying Filing Details

Total Spending

$650,000

Activities

4

Lobbyists

6

Gov't Entities

18

Filing Information
Filing UUID:
a2932449-d86b-4bf4-8b97-72e156da7087
Type:
Q1 - 1st Quarter - Report
Period:
2025 - 1st Quarter (Jan 1 - Mar 31)
Date Posted:
April 16, 2025 at 10:37 PM
Income:
$0
Expenses:
$650,000
Expense Method:
A
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Beth Anne Cole
Registrant
ASSOCIATION FOR ACCESSIBLE MEDICINES

Association representing the interests of the generic pharmaceutical industry.

Washington, District of Columbia
Client
ASSOCIATION FOR ACCESSIBLE MEDICINES
District of Columbia, United States of America
Lobbying Activities (4)
Activity 1
Copyright/Patent/Trademark

H.R._/S._: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R._/S._: Patent Eligibility Restoration Act. H.R._/S._: To address patent thickets. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. S._: A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. S.43: Skinny Labels, Big Savings Act. S.1040: Drug Competition Enhancement Act.

Lobbyists (5)
  • KARIN HESSLER
  • KATHERINE RAAB
  • PETER KELBEL
  • ILHAAM JAFFER
  • JOHN MURPHY
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Federal Trade Commission (FTC)
Activity 2
Medicare/Medicaid

Medicare Part D Reform. H.R._/S._: Ensuring Access to Lower-Cost Medicines for Seniors Act. H.R._/S._: Increasing Access to Biosimilars Act. Medicaid Rebate Penalty.

Lobbyists (6)
  • CRAIG BURTON
  • KARIN HESSLER
  • KATHERINE RAAB
  • PETER KELBEL
  • ILHAAM JAFFER
  • JOHN MURPHY
Government Entities (5)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • U.S. Trade Representative (USTR)
  • Centers For Medicare and Medicaid Services (CMS)
  • Natl Economic Council (NEC)
Activity 3
Pharmacy

Prescription Drug Costs. H.R.1843 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: A bill to provide for increased transparency in generic drug applications. H.R.1396: To amend the Internal Revenue Code of 1986 to establish the generic drugs and biosimilars production credit, and for other purposes. Drug Shortages. Biosimilar Interchangeability. H.R.1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. E-Labeling.

Lobbyists (6)
  • CRAIG BURTON
  • KARIN HESSLER
  • KATHERINE RAAB
  • PETER KELBEL
  • ILHAAM JAFFER
  • JOHN MURPHY
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Health & Human Services, Dept of (HHS)
  • Centers For Medicare and Medicaid Services (CMS)
Activity 4
Trade (domestic/foreign)

General Trade Issues. Drug Supply Chain. Country of Origin Labeling. Tariffs on Generic Medicines. Increasing Domestic Production of Generics and Biosimilars.

Lobbyists (5)
  • KARIN HESSLER
  • KATHERINE RAAB
  • PETER KELBEL
  • ILHAAM JAFFER
  • JOHN MURPHY
Government Entities (6)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • White House Office
  • U.S. Trade Representative (USTR)
  • Health & Human Services, Dept of (HHS)
  • ... and 1 more

Source: LDA.gov, data retrieved November 4, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.